Company Overview

Update
Founded:
2013
Headquarters:
New York, NY
Funding:
$33M
Categories:
Biotechnology

Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.

Description

Update

Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for outsized clinical effects in genetically defined patient populations. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery.

Current Team (1)

Update

Funding Rounds (1) - $33M

Update

Investors (2)

Update
  • 77f403d5e6a3df09250d1a3b3e814fa6

    Aisling Capital

    Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by..
  • B1ce9d2887c930e2d5d82b64a7eebcb9

    OrbiMed Advisors

    OrbiMed is ahealthcare-dedicated investment firm, with approximately $5 billion in assets under..

Offices/Locations (1)

Update
  • Office

    New York, NY

    USA